Book contents
- Bipolar DisordersBasic Mechanisms and Therapeutic ImplicationsThird Edition
- Bipolar Disorders
- Copyright page
- Contents
- Contributors
- Preface
- 1 Bipolar disorders in DSM-5: changes and implications for clinical research
- 2 Prospects for the development of animal models of bipolar disorder
- 3 An assessment of the catecholamine hypothesis of bipolar disorder
- 4 Serotonergic dysfunction in bipolar disorder
- 5 Involvement of the GABA and glutamate neurotransmitter systems in bipolar disorder
- 6 Oxidative stress and neuronal resilience – implications for the pathophysiology of bipolar disorder
- 7 Circuitry-specific hypermetabolism in the hippocampus of bipolar patients
- 8 The neuroendocrinology of stress in the pathophysiology of bipolar disorders
- 9 Brain imaging abnormalities in bipolar disorder
- 10 Sleep and circadian rhythms in bipolar disorders
- 11 The role of infectious agents in the causation of bipolar disorder
- 12 EEGs and ERPs in bipolar disorders
- 13 Genetic factors in the etiology of bipolar disorder
- 14 Neurocognitive findings in bipolar disorder: an update
- 15 Psychotherapeutic interventions in bipolar disorder
- 16 The kindling/sensitization model and the pathophysiology of bipolar disorder
- 17 Biological factors in bipolar disorder in childhood and adolescence
- 18 Biological factors in bipolar disorder in late life
- 19 Perspective for new pharmacological interventions
- 20 Physical health and metabolic dysfunction in bipolar disorder
- 21 Immune dysregulation in bipolar disorder
- Index
- References
1 - Bipolar disorders in DSM-5: changes and implications for clinical research
Published online by Cambridge University Press: 05 May 2016
Book contents
- Bipolar DisordersBasic Mechanisms and Therapeutic ImplicationsThird Edition
- Bipolar Disorders
- Copyright page
- Contents
- Contributors
- Preface
- 1 Bipolar disorders in DSM-5: changes and implications for clinical research
- 2 Prospects for the development of animal models of bipolar disorder
- 3 An assessment of the catecholamine hypothesis of bipolar disorder
- 4 Serotonergic dysfunction in bipolar disorder
- 5 Involvement of the GABA and glutamate neurotransmitter systems in bipolar disorder
- 6 Oxidative stress and neuronal resilience – implications for the pathophysiology of bipolar disorder
- 7 Circuitry-specific hypermetabolism in the hippocampus of bipolar patients
- 8 The neuroendocrinology of stress in the pathophysiology of bipolar disorders
- 9 Brain imaging abnormalities in bipolar disorder
- 10 Sleep and circadian rhythms in bipolar disorders
- 11 The role of infectious agents in the causation of bipolar disorder
- 12 EEGs and ERPs in bipolar disorders
- 13 Genetic factors in the etiology of bipolar disorder
- 14 Neurocognitive findings in bipolar disorder: an update
- 15 Psychotherapeutic interventions in bipolar disorder
- 16 The kindling/sensitization model and the pathophysiology of bipolar disorder
- 17 Biological factors in bipolar disorder in childhood and adolescence
- 18 Biological factors in bipolar disorder in late life
- 19 Perspective for new pharmacological interventions
- 20 Physical health and metabolic dysfunction in bipolar disorder
- 21 Immune dysregulation in bipolar disorder
- Index
- References
Summary
A summary is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
- Type
- Chapter
- Information
- Bipolar DisordersBasic Mechanisms and Therapeutic Implications, pp. 1 - 7Publisher: Cambridge University PressPrint publication year: 2016
References
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorder (3rd edn). Washington, DC: American Psychiatric Publishing; 1980.Google Scholar
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (5th edn). Arlington, VA: American Psychiatric Publishing; 2013.Google Scholar
Angst, J. Bipolar disorders in DSM-5: strengths, problems and perspectives. Intl J Bipolar Disord. 2013;1:12.CrossRefGoogle ScholarPubMed
Cosgrove, V.E., Suppes, T. Informing DSM-5: biological boundaries between bipolar I disorder, schizoaffective disorder, and schizophrenia. BMC Med. 2013;11:127.CrossRefGoogle ScholarPubMed
Feighner, J.P., Robins, E., Guze, S.B.,. et al. Diagnostic criteria for use in psychiatric research. Arch Gen Psychiatry. 1972;26:57–63.CrossRefGoogle ScholarPubMed
Feinstein, A. The pre-therapeutic classification of co-morbidity in chronic disease. J Chron Dis. 1970;23:455–68.CrossRefGoogle ScholarPubMed
Frances, A., Jones, K.D. Bipolar disorder type II revisited. Bipolar Disord. 2012;14(5):474–7.CrossRefGoogle ScholarPubMed
Frye, M.A., Grunze, H., Suppes, T. et al. A placebo-controlled evaluation of adjunctive modafinil in the treatment of bipolar depression. Am J Psychiatry. 2007;164(8):1242–9.CrossRefGoogle ScholarPubMed
Frye, M.A., McElroy, S.L., Prieto, M.L., et al. Clinical risk factors and serotonin transporter gene variants associated with antidepressant-induced mania. J Clin Psychiatry. 2015;76(2):174–80.CrossRefGoogle ScholarPubMed
Goldberg, J.F., Perlis, R.H., Bowden, C.L., et al. Manic symptoms during depressive episodes in 1,380 patients with bipolar disorder: findings from the STEP-BD. Am J Psychiatry. 2009;166(2):173–81.CrossRefGoogle Scholar
Insel, T., Cuthbert, B., Garvey, M., et al. Research domain criteria (RDoC): Toward a new classification framework for research on mental disorders. Am J Psychiatry. 2010;167(7):748–51.CrossRefGoogle Scholar
Ostacher, M.J. What can ICD-11 be that DSM-5 cannot? Aust N Z J Psychiatry. 2014;48(3):283–4.CrossRefGoogle ScholarPubMed
Perlis, R.H., Ostacher, M.J., Goldberg, J.F., et al. Transition to mania during treatment of bipolar depression. Neuropsychopharmacology. 2010;35(13):2545–52.CrossRefGoogle ScholarPubMed
Phillips, M.L., Kupfer, D.J. Bipolar disorder diagnosis: challenges and future directions. Lancet. 2013;381: 1663–71.CrossRefGoogle ScholarPubMed
Sheehan, D.V., McElroy, S.L., Harnett-Sheehan, K., et al. Randomized, placebo-controlled trial of risperidone for acute treatment of bipolar anxiety. J Affect Disord. 2009;115(3):376–85.CrossRefGoogle ScholarPubMed
Sheehan, D.V., Harnett-Sheehan, K., Hidalgo, R.B., et al. Randomized, placebo-controlled trial of quetiapine XR and divalproex ER monotherapies in the treatment of the anxious bipolar patient. J Affect Disord. 2013;145(1):83–94.CrossRefGoogle ScholarPubMed
Suppes, T., Mintz, J., McElroy, S.L., et al. Mixed hypomania in 908 patients with bipolar disorder evaluated prospectively in the Stanley Bipolar Treatment Network: A sex-specific phenomenon. Arch Gen Psychiatry. 2005;62(10):1089–96.CrossRefGoogle ScholarPubMed
Suppes, T., Frank, E., DePaulo, J.R., et al. Letter to the editor in response to 2012 article by Frances and Jones. Bipolar Disord. 2014a;16(2):214–15.CrossRefGoogle Scholar
Suppes, T., McElroy, S., Sheehan, D., et al. A randomized, double-blind, placebo-controlled study of ziprasidone monotherapy in bipolar disorder with co occurring lifetime panic or generalized anxiety disorder. J Clin Psychiatry. 2014b;75(1):77–84.CrossRefGoogle ScholarPubMed
Swann, A.C., Lafer, B., Perugi, G., et al. Bipolar mixed states: An International Society for Bipolar Disorders task force report of symptom structure, course of illness and diagnosis. Am J Psychiatry. 2013;170:31–42.CrossRefGoogle ScholarPubMed